PAP
RVPH

Persistent Asset Partners’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Persistent Asset Partners’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,695
Closed -$330K – 436
2025
Q3 		$219K Sell
29,695
-2,364
-7% -$20.1K 0.15% 128
2025
Q2 		$244K Buy
32,059
+24,043
+300% +$374K 0.18% 103
2025
Q1 		$153K Sell
8,016
-43
-0.5% -$1.35K 0.13% 106
2024
Q4 		$305K Buy
+8,059
New +$224K 0.25% 81

Other funds holding RVPH

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Persistent Asset Partners's RVPH Position: Q4 2025 in Review

Persistent Asset Partners sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q4 2025, closing a stake of 29,695 shares — an estimated $330K sold.

Persistent Asset Partners first reported a position in RVPH in Q4 2024 and held it in 4 quarters. The position peaked at $305K in Q4 2024. 48 funds tracked by Wall St. Rank hold RVPH as of Q4 2025.

  • Persistent Asset Partners reported no remaining REVIVA PHARMA HLDGS INC position as of Q4 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 29,695 REVIVA PHARMA HLDGS INC shares in Q4 2025, an estimated $330K.
  • Persistent Asset Partners first reported a position in REVIVA PHARMA HLDGS INC in Q4 2024 and held it in 4 quarters.
  • Persistent Asset Partners's REVIVA PHARMA HLDGS INC position peaked at $305K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q4 2025.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.